Bottom line
BBP vs PBE: the short answer
BBP (Virtus Biotech ETF) and PBE (Invesco Biotechnology & Genome ETF) are quite different portfolios: only about 16% of their top holdings (by weight) are shared.
But BBP is far broader, holding 70 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
BBP is cheaper at 0.34% vs 0.59% — a difference of $25 a year per $10,000 invested.
Over five years, BBP returned +8.4% a year vs +3.4% for PBE.
Updated Nov 19, 2026
BBP vs PBE side by side
| BBP | PBE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Virtus | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.34% | 0.59% |
| Annual cost per $10k | $34 | $59 |
| 10-yr cost on $10k (prospectus) | $431 | $738 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +32.8% | +24.7% |
| 5-yr return (annualized) | +8.4% | +3.4% |
| 10-yr return (annualized) | +10.0% | +5.2% |
| Best quarter | +28.2% | +25.3% |
| Worst quarter | −23.0% | −24.3% |
| Net assets (fund) | $98.5M | $281.9M |
| Number of holdings | 70 | 33 |
| Portfolio turnover | 29% | 103% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBP | PBE | Difference |
|---|---|---|---|
| 2025 | +32.8% | +24.7% | +8.1% |
| 2024 | +3.6% | +1.1% | +2.5% |
| 2023 | +17.4% | +3.7% | +13.8% |
| 2022 | +1.0% | −10.8% | +11.7% |
| 2021 | −8.2% | +1.6% | −9.8% |
| 2020 | +22.2% | +25.5% | −3.3% |
| 2019 | +24.9% | +18.3% | +6.6% |
| 2018 | −13.8% | +0.2% | −14.0% |
| 2017 | +23.8% | +22.4% | +1.4% |
| 2016 | +6.5% | −23.0% | +29.5% |
Source: Fund prospectus bar charts
Holdings overlap
5 of BBP's top 25 holdings also appear in PBE's top 25.
| Holding | BBP | PBE |
|---|---|---|
| Regeneron Pharmaceuticals | 1.72% | 5.47% |
| Protagonist Therapeutics Inc | 1.71% | 3.40% |
| Acadia Pharmaceuticals Inc | 1.69% | 3.02% |
| Halozyme Therapeutics Inc | 1.64% | 2.98% |
| Incyte Corp | 1.52% | 3.06% |
Source: SEC Form N-PORT
BBP top 10
- Crinetics Pharmaceuticals Inc — 3.34%
- Kiniksa Pharmaceuticals International Plc — 1.97%
- Verastem Inc — 1.95%
- Precigen Inc — 1.94%
- Omeros Corp — 1.87%
- Nuvation Bio Inc — 1.77%
- Regeneron Pharmaceuticals — 1.72%
- Protagonist Therapeutics Inc — 1.71%
- Acadia Pharmaceuticals Inc — 1.69%
- Bridgebio Pharma Inc — 1.65%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between BBP and PBE?
Which is cheaper, BBP or PBE?
Should I own both BBP and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.